These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21668303)

  • 21. Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring.
    Dander E; Lucchini G; Vinci P; Introna M; Masciocchi F; Perseghin P; Balduzzi A; Bonanomi S; Longoni D; Gaipa G; Belotti D; Parma M; Algarotti A; Capelli C; Golay J; Rovelli A; Rambaldi A; Biondi A; Biagi E; D'Amico G
    Leukemia; 2012 Jul; 26(7):1681-4. PubMed ID: 22289986
    [No Abstract]   [Full Text] [Related]  

  • 22. Hierarchical organization and regulation of the hematopoietic stem cell osteoblastic niche.
    Wang H; Zhang P; Liu L; Zou L
    Crit Rev Oncol Hematol; 2013 Jan; 85(1):1-8. PubMed ID: 22743345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Application of mesenchymal stem cell in immunotherapy--review].
    Liao LM; Han Q; Zhao CH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):158-63. PubMed ID: 15748459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mesenchymal stem cells for graft-versus-host disease: a double edged sword?
    Vianello F; Dazzi F
    Leukemia; 2008 Mar; 22(3):463-5. PubMed ID: 18335000
    [No Abstract]   [Full Text] [Related]  

  • 25. Mesenchymal stem cell therapies in the treatment of musculoskeletal diseases.
    Bashir J; Sherman A; Lee H; Kaplan L; Hare JM
    PM R; 2014 Jan; 6(1):61-9. PubMed ID: 24439148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mesenchymal stem cells alter migratory property of T and dendritic cells to delay the development of murine lethal acute graft-versus-host disease.
    Li H; Guo Z; Jiang X; Zhu H; Li X; Mao N
    Stem Cells; 2008 Oct; 26(10):2531-41. PubMed ID: 18635870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The mesenchymal stromal cells dilemma--does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?
    Galipeau J
    Cytotherapy; 2013 Jan; 15(1):2-8. PubMed ID: 23260081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mesenchymal stem cells enhance the induction of mixed chimerism and tolerance to rat hind-limb allografts after bone marrow transplantation.
    Pan H; Zhao K; Wang L; Zheng Y; Zhang G; Mai H; Han Y; Yang L; Guo S
    J Surg Res; 2010 May; 160(2):315-24. PubMed ID: 19524257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transplanted mesenchymal stem cells can inhibit the three developmental stages of murine acute graft-versus-host disease.
    Li H; Guo Z; Zhu H; Li XS; Jiang X; Yao H; Wang X; Liao L; Liu Y; Wu Y; Zhang Y; Mao N
    In Vivo; 2010; 24(5):659-66. PubMed ID: 20952730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mesenchymal stromal cell supported umbilical cord blood ex vivo expansion enhances regulatory T cells and reduces graft versus host disease.
    Fan X; Gay FP; Ong SY; Ang JM; Chu PP; Bari S; Lim TK; Hwang WY
    Cytotherapy; 2013 May; 15(5):610-9. PubMed ID: 23419678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mesenchymal stem cells: properties and role in clinical bone marrow transplantation.
    Le Blanc K; Ringdén O
    Curr Opin Immunol; 2006 Oct; 18(5):586-91. PubMed ID: 16879957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guest editorial: Human mesenchymal stromal/stem cell (MSC).
    Miura Y
    Int J Hematol; 2016 Feb; 103(2):119-21. PubMed ID: 26699363
    [No Abstract]   [Full Text] [Related]  

  • 33. Biologic characteristics of mesenchymal stromal cells and their clinical applications in pediatric patients.
    Pelagiadis I; Dimitriou H; Kalmanti M
    J Pediatr Hematol Oncol; 2008 Apr; 30(4):301-9. PubMed ID: 18391700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How do mesenchymal stromal cells exert their therapeutic benefit?
    Horwitz EM; Dominici M
    Cytotherapy; 2008; 10(8):771-4. PubMed ID: 19089685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of acute graft versus host disease with mesancyhmal stem cells: Questions and answers.
    Bozdağ SC; Tekgündüz E; Altuntaş F
    Transfus Apher Sci; 2016 Feb; 54(1):71-5. PubMed ID: 26969103
    [No Abstract]   [Full Text] [Related]  

  • 36. Stem cell microenvironment as a potential therapeutic target.
    Lee CC; Kim KD
    Regen Med; 2012 Jan; 7(1):3-5. PubMed ID: 22168488
    [No Abstract]   [Full Text] [Related]  

  • 37. Therapeutic potential of intravenously administered human mesenchymal stromal cells.
    Kollar K; Seifried E; Henschler R
    Hamostaseologie; 2011 Nov; 31(4):269-74. PubMed ID: 22064918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mesenchymal stromal cells: are they ready for prime time?
    Kamani NR
    Transfusion; 2016 Apr; 56(4):1S. PubMed ID: 27079317
    [No Abstract]   [Full Text] [Related]  

  • 39. Risk of tumorigenicity in mesenchymal stromal cell-based therapies--bridging scientific observations and regulatory viewpoints.
    Barkholt L; Flory E; Jekerle V; Lucas-Samuel S; Ahnert P; Bisset L; Büscher D; Fibbe W; Foussat A; Kwa M; Lantz O; Mačiulaitis R; Palomäki T; Schneider CK; Sensebé L; Tachdjian G; Tarte K; Tosca L; Salmikangas P
    Cytotherapy; 2013 Jul; 15(7):753-9. PubMed ID: 23602595
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.